Publication Name	World Journal of Clinical Cases
Manuscript ID	1794
Country	Italy

Received	2013-01-07 08:56
Peer-Review Started	2013-01-07 16:31
First Decision by Editorial Office Director
Return for Revision	2013-02-04 18:47
Revised	2013-02-18 01:13
Publication Fee Transferred
Second Decision by Editor	2013-03-28 17:25
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2013-03-29 11:55
Articles in Press
Edit the Manuscript by Language Editor	2013-04-04 01:44
Typeset the Manuscript	2013-05-14 21:51
Publish the Manuscript Online	2013-05-16 14:52

ISSN	2307-8960 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Biological therapy for dermatological manifestations of inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	Maddalena Zippi, Roberta Pica, Daniela De Nitto and Paolo Paoluzi
Funding Agency and Grant Number
Corresponding Author	Maddalena Zippi, MD, Unit of Gastroenterology and Digestive Endoscopy, Sandro Pertini Hospital, Via dei Monti Tiburtini 385, 00157 Rome, Italy. maddyzip@yahoo.it
Key Words	Biological therapies; Erythema nodosum; Inflammatory bowel disease; Psoriasis; Pyoderma gangrenosum
Core Tip	Ulcerative colitis and Crohn’s disease are the best known forms of inflammatory bowel disease (IBD) and are considered immune-mediated disorders of unknown etiology that primarily affect the gastrointestinal tract. In addition, other organ systems can be involved, such as skin. Erythema nodosum, pyoderma gangrenosum and psoriasis are the dermatological comorbidities often associated with it. The anti-tumor necrosis factor (TNF)-α drugs (infliximab and adalimumab) have significantly changed the management of these conditions. In this brief review, we provide an overview on the prevalence and clinical aspects of the more commonly reported skin manifestations of IBD and the role of TNF-α inhibitors in their treatment.
Publish Date	2013-05-16 14:52
Citation	Zippi M, Pica R, De Nitto D, Paoluzi P. Biological therapy for dermatological manifestations of inflammatory bowel disease. World J Clin Cases 2013; 1(2): 74-78
URL	http://www.wjgnet.com/2307-8960/full/v1/i2/74.htm
DOI	http://dx.doi.org/10.12998/wjcc.v1.i2.74

Full Article (PDF)	WJCC-1-74.pdf
Manuscript File	1794-Review.doc
Answering Reviewers	1794-Answering reviewers.doc
Copyright License Agreement	1794-Copyright assignment.doc
Peer-review Report	1794-Peer review(s).pdf
Scientific Editor Work List	1794-Scientific editor work list.doc